Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS malignancies consortium pilot study 019

Clinical Lymphoma and Myeloma

Volumn 6, Issue 5, 2006, Pages 399-402

  Aboulafia, David M ^a   Ratner, Lee ^b   Miles, Steven A ^c   Harrington Jr , William J ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

Antiretroviral therapy; Central nervous system lesions; Ganciclovir; Human immunodeficiency virus; Interleukin 2; Zidovudine

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; GANCICLOVIR; HYDROXYUREA; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFECTION; NONHUMAN; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME; VIRUS LOAD;

EID: 33646592569     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.017     Document Type: Article

References (27)

1. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003, 4:110-119.
2. Cingolani A, De Luca A, Larocca LM, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. J Natl Cancer Inst 1998; 90:364-369.
3. Skolasky RL, Dal Pan GJ, Olivi A, et al. HIV-associated primary CNS lymorbidity and utility of brain biopsy. J Neurol Sci 1999; 163:32-38.
4. Camilleri-Broet S, Davi F, Feuillard J, et al. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol 1997,28:367-374.
5. Thompson MP Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10:803-821.
6. Bashir R, Luka J, Cheloha K, et al. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology 1993; 43:2358-2362.
7. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency viru-related primary central nervous system lymphoma. factors influencing survival in 111 patients. Cancer 2004; 100:2627-2636.
8. Flinn IW, Ambinder RF. AIDS primary central nervous system lymphoma. Curr Opin Oncol 1996; 8:373-376.
9. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 2003; 17:1787-1793.
10. Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir; and interleukin 2. AIDS Res Hum Retroviruses 1999; 15:713-719.
11. Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 2003; 63:965-971.
12. Lorberboym M, Wallach F. Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39:1366-1369.
13. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034-5043.
14. Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis 2002; 34:1660-1662.
15. Raez LE, Patel P, Feun L, et al. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS) related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 1998; 9:199-208.
16. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338:969-973.
17. Feng WH, Hong G, Delecluse HJ, et al. Lytic induction therapy for Epstein Barr virus-positive B-cell lymphomas. J Virol 2004; 78:1893-1902.
18. Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001; 45:2082-2091.
19. Mentzer SJ, Fingeroth J, Reilly JJ, et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Ce#s Mol Dis 1998; 24:114-123.
20. Xue SA, Labrecque LG, Lu QL, et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 2002; 99:635-643.
21. Weinberg A. Li S, Palmer M, et al. Quantitative CSF PCR in Epstein-Barr virus infections of the central nervous system. Ann Neurol 2002; 52:543-548.
22. Kurokawa M, Ghosh SK, Ramos JC, et al. Azidothymidine inhibits NF-kappa B and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood 2005; 106:235-40.
23. Slobod KS, Taylor GH, Sandlund JT, et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000; 356:1493-1494.
24. Torre D, Speranza F, Martegani R. Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection. HIV Med 2005; 6:66-78.
25. Hoffmann C, Tabrizion S, Wolfe, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15:2119.
26. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2005 [Epub ahead of print].
27. Kaplan LD, Lee JY, Ambinder RE et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543.